XO1
Hatfield
About XO1
XO1 Ltd is a biotechnology companied formed specifically to develop ichorcumab. It is a virtual company, with no offices or laboratory space, and operates by engaging high quality contract research and development specialists in Europe and the US, managed by a small team of experienced drug developers. Properly managed, virtual drug development not only controls costs but maximizes quality through flexible selection of the most appropriate supplier for each individual task. Read more: XO1 Ltd raises $11 million from Index Ventures to develop the 'holy grail' of anticoagulant drugs - FierceBiotech http://www.fiercebiotech.com/press-releases/xo1-ltd-raises-11-million-index-ventures-develop-holy-grail-anticoagulant-d#ixzz2WSG7D0Bu Subscribe at FierceBiotech
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $11.0M
- Funding stage: M&A
- Last round: Series A (Jun 2013)
- Website: xo1.co.uk
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/xo1-615838 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.